These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34311775)

  • 1. Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status.
    Babapour Mofrad R; Scheltens P; Kim S; Kang S; Youn YC; An SSA; Tomassen J; van Berckel BNM; Visser PJ; van der Flier WM; Teunissen CE
    Alzheimers Res Ther; 2021 Jul; 13(1):133. PubMed ID: 34311775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity.
    Pyun JM; Ryu JS; Lee R; Shim KH; Youn YC; Ryoo N; Han SW; Park YH; Kang S; An SSA; Kim S
    Clin Interv Aging; 2021; 16():749-755. PubMed ID: 33958861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Oligomer β-Amyloid and White Matter Microstructural Integrity in Cognitively Normal Older Adults According to Cerebral Amyloid Deposition.
    Wang SM; Kang DW; Um YH; Kim S; Lee CU; Scheltens P; Lim HK
    J Prev Alzheimers Dis; 2023; 10(4):837-846. PubMed ID: 37874106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer's disease spectrum.
    Wang SM; Kang DW; Um YH; Kim S; Lee CU; Scheltens P; Lim HK
    Alzheimers Res Ther; 2024 Mar; 16(1):55. PubMed ID: 38468313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data.
    Youn YC; Kim HR; Shin HW; Jeong HB; Han SW; Pyun JM; Ryoo N; Park YH; Kim S
    BMC Med Inform Decis Mak; 2022 Nov; 22(1):286. PubMed ID: 36344984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer's disease.
    Meng X; Li T; Wang X; Lv X; Sun Z; Zhang J; Su F; Kang S; Kim S; An SSA; Yu X; Zhang C; Wang H
    Alzheimers Res Ther; 2019 Oct; 11(1):89. PubMed ID: 31651358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood Amyloid-β Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study.
    Youn YC; Lee BS; Kim GJ; Ryu JS; Lim K; Lee R; Suh J; Park YH; Pyun JM; Ryu N; Kang MJ; Kim HR; Kang S; An SSA; Kim S
    J Alzheimers Dis; 2020; 75(2):493-499. PubMed ID: 32310175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.
    Schindler SE; Bollinger JG; Ovod V; Mawuenyega KG; Li Y; Gordon BA; Holtzman DM; Morris JC; Benzinger TLS; Xiong C; Fagan AM; Bateman RJ
    Neurology; 2019 Oct; 93(17):e1647-e1659. PubMed ID: 31371569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous Aβ peptide promote Aβ oligomerization tendency of spiked synthetic Aβ in Alzheimer's disease plasma.
    Choi Y; Joh Y; Ryu JS; Kim K; Seo D; Kim S
    Mol Cell Neurosci; 2021 Mar; 111():103588. PubMed ID: 33422673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
    Janelidze S; Teunissen CE; Zetterberg H; Allué JA; Sarasa L; Eichenlaub U; Bittner T; Ovod V; Verberk IMW; Toba K; Nakamura A; Bateman RJ; Blennow K; Hansson O
    JAMA Neurol; 2021 Nov; 78(11):1375-1382. PubMed ID: 34542571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
    Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M;
    Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease.
    Xia W; Yang T; Shankar G; Smith IM; Shen Y; Walsh DM; Selkoe DJ
    Arch Neurol; 2009 Feb; 66(2):190-9. PubMed ID: 19204155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reference interval and the role of plasma oligomeric beta amyloid in screening of risk groups for cognitive dysfunction at health checkups.
    Nah EH; Cho S; Park H; Noh D; Hwang I; Cho HI
    J Clin Lab Anal; 2021 Sep; 35(9):e23933. PubMed ID: 34342379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.
    Hu Y; Kirmess KM; Meyer MR; Rabinovici GD; Gatsonis C; Siegel BA; Whitmer RA; Apgar C; Hanna L; Kanekiyo M; Kaplow J; Koyama A; Verbel D; Holubasch MS; Knapik SS; Connor J; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE; West T
    JAMA Netw Open; 2022 Apr; 5(4):e228392. PubMed ID: 35446396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
    JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up Comparisons of Two Plasma Biomarkers of Alzheimer's Disease, Neurofilament Light Chain, and Oligomeric Aβ: A Pilot Study.
    Shim Y
    Curr Alzheimer Res; 2023; 20(10):715-724. PubMed ID: 38299421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.